Open AccessNo association of rs1065852 and rs3892097 polymorphisms gene CYP2D6 with treatment resistant schizophrenia
Author(s) -
Д. Н. Сосин,
М. В. Иванов,
Л. М. Муслимова,
Dmitriy V. Ivashchenko,
Д. А. Сычев
Publication year - 2019
Publication title -
obozrenie psihiatrii i medicinskoj psihologii im. v.m. behtereva/obozrenie psihiatrii i medicinskoj psihologii imeni v.m. behtereva
Language(s) - English
Resource type - Journals
eISSN - 2713-055X
pISSN - 2313-7053
DOI - 10.31363/2313-7053-2019-4-1-128-129
Subject(s) - schizophrenia (object oriented programming) , cyp2d6 , medicine , psychiatry , pharmacogenetics , polymorphism (computer science) , gene , oncology , pharmacology , genetics , biology , genotype , cytochrome p450 , metabolism
According to modern data, about a third of patients suffering from schizophrenia are considered treatment resistant. The metabolism of about 20% of medicines and mainly psychotropic drugs is caused by the isoenzyme CYP2D6. This article presents the data of the CYP2D6 gene study as biomarkers for the treatment resistant schizophrenia. The study included 130 patients, men (65.4%) and women (34.6%) aged 18 to 60 years with schizophrenia. Based on the results, we found no effect of rs1065852 and rs3892097 polymorphisms gene CYP2D6 on treatment resistant schizophrenia.